Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data
Abstract Background The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS). In 2021, the long-acting C5-inhibitor ravulizumab was approved, extending intervals of intravenous treatment from two to eigh...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMC
2024-06-01
|
| Σειρά: | BMC Nephrology |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1186/s12882-024-03638-3 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|